End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
259.6 CNY | +0.55% | -0.77% | +42.38% |
04-26 | Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80% | MT |
04-25 | Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- With an expected P/E ratio at 72.11 and 48.34 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+42.38% | 4.47B | - | ||
+5.48% | 71.19B | A | ||
+12.55% | 9.3B | A- | ||
-13.75% | 5.01B | A- | ||
+4.51% | 3.96B | B- | ||
+21.10% | 2.44B | B | ||
-19.05% | 2.41B | C- | ||
-28.72% | 2.23B | - | ||
+11.13% | 2.02B | - | - | |
+6.53% | 1.69B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300573 Stock
- Ratings Shenyang Xingqi Pharmaceutical Co.,Ltd.